Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across non–small cell lung cancer (NSCLC) histologies and is Food and Drug Administration approved for treatment of metastatic squamous NSCLC with progre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Appl Immunohistochem Mol Morphol
Autors principals: Phillips, Therese, Simmons, Pauline, Inzunza, Hector D., Cogswell, John, Novotny, James, Taylor, Clive, Zhang, Xiaoling
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2015
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4561627/
https://ncbi.nlm.nih.gov/pubmed/26317305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAI.0000000000000256
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars